PI3K Inhibitors: Alpelisib is a PI3K inhibitor indicated for use (typically in combination with fulvestrant) in postmenopausal women and men with HR+ HER2-negative, PIK3CA-mutated advanced or metastatic BC [76]. Here, PIK3CA is linked to breast cancer.